November 28, 2016 - By Ruchi Gupta · 0 Comments
Illumina Inc (NASDAQ:ILMN) institutional sentiment decreased to 1.07 in 2016 Q2. Its down -0.03, from 1.1 in 2016Q1. The ratio turned negative, as 237 active investment managers increased or opened new positions, while 216 cut down and sold their positions in Illumina Inc. The active investment managers in our partner’s database reported: 137.98 million shares, down from 143.46 million shares in 2016Q1. Also, the number of active investment managers holding Illumina Inc in their top 10 positions decreased from 7 to 6 for a decrease of 1. Sold All: 66 Reduced: 150 Increased: 191 New Position: 46.
Illumina, Inc. offers sequencing and array solutions for genetic analysis. The company has a market cap of $19.97 billion. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. It has a 45.2 P/E ratio. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
The stock increased 0.57% or $0.76 on November 25, hitting $135.19. Illumina, Inc. (NASDAQ:ILMN) has declined 5.51% since April 25, 2016 and is downtrending. It has underperformed by 11.52% the S&P500.
Analysts await Illumina, Inc. (NASDAQ:ILMN) to report earnings on February, 7. They expect $0.81 EPS, 0.00% or $0.00 from last year’s $0.81 per share. ILMN’s profit will be $119.65M for 41.73 P/E if the $0.81 EPS becomes a reality. After $0.97 actual EPS reported by Illumina, Inc. for the previous quarter, Wall Street now forecasts -16.49% negative EPS growth.
According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”
Wellington Shields & Co. Llc holds 13% of its portfolio in Illumina, Inc. for 149,151 shares. Bender Robert & Associates owns 60,067 shares or 5.95% of their US portfolio. Moreover, Edgewood Management Llc has 5.01% invested in the company for 4.86 million shares. The United Kingdom-based Baillie Gifford & Co has invested 4.66% in the stock. Messner & Smith Theme Value Investment Management Ltd Ca, a California-based fund reported 16,142 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 24 sales for $15.18 million net activity.
Ratings analysis reveals 30% of Illumina Inc’s analysts are positive. Out of 23 Wall Street analysts rating Illumina Inc, 7 give it “Buy”, 2 “Sell” rating, while 14 recommend “Hold”. The lowest target is $116 while the high is $250. The stock’s average target of $170.80 is 26.34% above today’s ($135.19) share price. ILMN was included in 47 notes of analysts from July 22, 2015. Leerink Swann downgraded it to “Market Perform” rating and $185 target price in Thursday, October 1 report. The rating was downgraded by Bank of America on Tuesday, April 19 to “Neutral”. Cantor Fitzgerald initiated the stock with “Buy” rating in Wednesday, August 26 report. The rating was maintained by Cowen & Co with “Outperform” on Tuesday, April 19. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Buy” rating by Canaccord Genuity on Wednesday, July 22. The rating was downgraded by Wells Fargo to “Market Perform” on Thursday, January 7. The firm has “Equal-Weight” rating by Morgan Stanley given on Tuesday, April 19. The stock has “Neutral” rating given by Janney Capital on Wednesday, July 22. The company was maintained on Tuesday, April 19 by Barclays Capital. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Buy” rating by BTIG Research on Thursday, August 20.
Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.
More recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Fool.com which released: “Is Illumina Inc. a Buffett Stock?” on November 08, 2016. Also Fool.com published the news titled: “Illumina Inc. Is Floundering: Here’s What Management Had to Say” on November 04, 2016. Fool.com‘s news article titled: “Illumina Inc. Q3 Weighed Down by Sluggish High-Throughput System Sales” with publication date: November 02, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta